The 5-HT 6 receptor is a promising target for cognitive disorders, in particular for Alzheimer's disease (AD). The high affinity and selective 5-HT 6 receptor antagonist idalopirdine (Lu AE58054) is currently in development for mild-moderate AD as adjunct therapy to acetylcholinesterase inhibitors (AChEIs). We studied the effects of idalopirdine alone and in combination with the AChEI donepezil on cortical function using two in vivo electrophysiological methods. Neuronal network oscillations in the frontal cortex were measured during electrical stimulation of the brainstem nucleus pontis oralis (nPO) in the anesthetized rat and by an electroencephalogram (EEG) in the awake, freely moving rat. In conjunction with the EEG study, we investigated the effects of idalopirdine and donepezil on sleep-wake architecture using telemetric polysomnography. Idalopirdine (2 mg/kg i.v.) increased gamma power in the medial prefrontal cortex (mPFC) during nPO stimulation. Donepezil (0.3 and 1 mg/kg i.v.) also increased cortical gamma power and pretreatment with idalopirdine (2 mg/kg i.v.) potentiated and prolonged the effects of donepezil. Similarly, donepezil (1 and 3 mg/kg s.c.) dose-dependently increased frontal cortical gamma power in the freely moving rat and pretreatment with idalopirdine (10 mg/kg p.o.) augmented the effect of donepezil 1 mg/kg. Analysis of the sleep-wake architecture showed that donepezil (1 and 3 mg/kg s.c.) dose-dependently delayed sleep onset and decreased the time spent in both REM and non REM sleep stages. In contrast, idalopirdine (10 mg/kg p.o.) did not affect sleep-wake architecture nor the effects of donepezil. In summary, we show that idalopirdine potentiates the effects of donepezil on frontal cortical gamma oscillations, a pharmacodynamic biomarker associated with cognition, without modifying the effects of donepezil on sleep. The increased cortical excitability may contribute to the procognitive effects of idalopirdine in donepezil-treated AD patients.
Introduction
During the course of the progressive neurodegeneration in Alzheimer's disease (AD) multiple neurotransmitter systems are affected. Today, symptomatic treatment for the cognitive deficits in AD targets either cholinergic (acetylcholinesterase inhibitors; AChEIs) or glutamatergic (NMDA receptor antagonist, memantine) transmission, however treatment with a single symptomatic agent has shown insufficient efficacy (Birks and Harvey, 2006; Raina et al., 2008; Tan et al., 2014) . Therefore, treatment of a disease with a complex pathophysiology like AD may require the combination of several therapies, with complementary mechanisms of action.
Modulation of serotonergic signaling has been implicated as a possible therapeutic strategy for AD (Ramirez et al., 2014; Claeysen et al., 2015) . Indeed, the serotonergic system is involved in the regulation of learning and memory (Meneses and Liy-Salmeron, 2012; Meneses, 2013; Schmitt et al., 2006) and there is prominent degeneration of serotonergic neurons in AD (Bowen et al., 1983; Lai et al., 2002; Nazarali and Reynolds, 1992) . Of the many serotonin (5-HT) receptor subtypes, the 5-HT 6 receptor has emerged as a promising new target for the treatment of cognitive deficits in AD (Ramirez, 2013) . This receptor was discovered in 1993 as one of the serotonin receptor superfamily, being positively coupled to adenylate cyclase via the G-protein GaS (Monsma, Jr. et al., 1993; Ruat et al., 1993) . The near exclusive localization in the brain combined with expression in areas that mediate cognitive processing (hippocampus, cortex, striatum) make the 5-HT 6 receptor an attractive target for pharmacotherapy in cognitive disorders Roberts et al., 2002; Hirst et al., 2003; Parker et al., 2012) . In a recent study, we demonstrated by double in-situ hybridization that the 5-HT 6 receptor is located on GABAergic medium spiny neurons in the striatum and on glutamatergic pyramidal cells, as well as on subsets of GABA-ergic interneurons, throughout the cortical layers and in the hippocampus (Helboe et al., 2015) . This places the 5-HT 6 receptor in a position to regulate the balance between excitatory and inhibitory signaling (Dawson et al. 2000 (Dawson et al. , 2001 Chuang et al., 2006; Schechter et al., 2008) , which is important given that in AD patients as well as AD transgenic animal models, there is evidence for an imbalance between excitation and inhibition leading to altered activity of cortical and hippocampal networks (Palop et al., 2006 (Palop et al., , 2007 Goutagny and Krantic, 2013) . In addition, through effects on GABA-ergic and glutamatergic signaling, antagonism of the 5-HT 6 receptor results in the regulation of several additional neurotransmitter systems, e.g. cholinergic and monoaminergic signaling (Lacroix et al., 2004; Chuang et al., 2006; Schechter et al., 2008; Dawson, 2011) . A wealth of preclinical studies have demonstrated the procognitive potential of 5-HT 6 receptor antagonists and a few have now transitioned to clinical development for the treatment of AD (Mitchell and Neumaier, 2005; Fone, 2008; Arnt et al., 2010; Meneses et al., 2011; Maher-Edwards et al., 2011; Ramirez, 2013; Wilkinson et al., 2014) . The use of a 5-HT 6 receptor antagonist as adjunct therapy to treatment with AChEIs appears a particularly promising approach for the treatment of AD. Preclinical studies have suggested that 5-HT 6 receptor antagonists potentiate the procognitive and neurochemical effects of AChEIs (Dawson, 2011; de Bruin et al., 2011; Marcos et al., 2008; Herrik et al., 2016) and the potential benefit of this combination treatment has been demonstrated in two Phase II clinical studies in moderate AD (Maher-Edwards et al., 2011; Wilkinson et al., 2014) . Idalopirdine (Lu AE58054), a high affinity and selective 5-HT 6 receptor antagonist, is the most advanced compound in Phase III development for mild-moderate AD as an adjunctive therapy to AChEIs (Wilkinson et al., 2014) .
Synchronous activity of neuronal networks is critical for cognitive function and can be measured as neuronal oscillations in an electroencephalogram (EEG) (Draguhn et al., 2014) . Of particular interest are hippocampal oscillations in the theta (4e8 Hz) frequency range and hippocampal and cortical oscillations in the gamma (30e90 Hz) frequency range as these are each associated with multiple aspects of cognitive function (Bland, 1986; Colgin et al., 2009; Jutras et al., 2009; Nyhus and Curran, 2010; Jensen et al., 2007) . In mild-moderate AD, oscillatory changes that are most consistently described include a reduction of cortical EEG power in the alpha and gamma bands and clinical studies have shown a partial normalization of the oscillatory activity with AChEI treatment (reviewed by: Babiloni et al., 2013; Basar et al., 2013) . In the laboratory rodent, compounds classically termed cognition enhancers have been shown to elicit a "fingerprint" of enhanced theta and gamma oscillations in the cortical EEG (Ahnaou et al., 2014) . In the anesthetized rat, stimulation of the brainstem reticular formation activates an ascending pathway from the nucleus pontis oralis (nPO), which enhances theta and gamma oscillations in the hippocampus through stimulation of the medial septum/ diagonal band of Broca (Bland and Oddie, 1998; Vertes, 1981; Stoiljkovic et al., 2015) and may also increase gamma oscillations in the prefrontal cortex (PFC) through the subsequent monosynaptic excitatory inputs from the hippocampus (Thierry et al., 2000) as well as parallel thalamocortical projections (Steriade, 1999) . In the hippocampus, theta and gamma oscillations evoked during stimulation of the brainstem reticular formation are sensitive to pharmacological agents with procognitive properties (McNaughton et al., 2007) such as donepezil (Kinney et al., 1999) and memantine (Guadagna et al., 2012) . In a recent study, we have demonstrated that the 5-HT 6 receptor antagonist idalopirdine potentiates the effects of the AChEI donepezil on oscillatory activity in the hippocampus during stimulation of the nPO (Herrik et al., 2016) . This may constitute one of the mechanisms through which the compounds have a coordinated effect on cognition. Due to the well-established coherence between the dorsal hippocampus and the medial PFC (mPFC) during brainstem stimulation (Kiss et As a novel approach, we therefore investigated whether cortical gamma oscillations elicited by nPO stimulation are sensitive to pharmacological agents with procognitive properties. The present study investigates the effects of idalopirdine alone, and in combination with donepezil, on oscillatory activity in the frontal cortex, using two distinct in vivo electrophysiological approaches: Neuronal oscillations in the mPFC during nPO stimulation in the anesthetized rat, and spontaneous cortical qEEG in the awake, freely moving rat. In addition, we studied the effects of both compounds on sleepwake architecture in conjunction with the qEEG study as both the cholinergic and serotonergic systems are known to play a crucial role in sleep-wake regulation (Monti, 2010; Portas et al., 2000; Jones, 1993; Hobson et al., 1993) .
Methods
2.1. Brainstem induced neuronal oscillations in mPFC of the anesthetized rat 2.1.1. Animals All experiments were performed in accordance with Danish legislative guidelines and were approved by The Animal Experimentation Expectorate (Dyreforsøgstilsynet) and Lundbeck's Institutional Animal Care and Use Committee (IACUC). Male Sprague-Dawley rats (Charles River) were used in the present study. Rats (weight 250e400 g) were housed under standard temperature (22 ± 1.5 C) and humidity (55e65%) controlled laboratory conditions with food and water available ad libitum in a 12 h light/dark cycle (lights on at 06:00 h).
Drugs
Idalopirdine (IDL, Lundbeck) was dosed at 1 or 2 mg/kg in a 5% glucose vehicle (1 ml/kg). Donepezil (DPZ, synthesized at Lundbeck) was dosed 60 min after IDL or vehicle (veh) at 0.3 mg/kg or 1 mg/kg in 0.9% saline vehicle (1 ml/kg). All drugs and vehicles were administered intravenously (i.v.) through a femoral vein cannula in urethane anesthetized rats. The following dosing paradigms were used in the nPO stimulation assay (treatment 1 followed by treatment 2): veh/veh, veh/DPZ0.3, IDL1/DPZ0.3, IDL2/DPZ0.3, veh/ DPZ1, IDL2/DPZ1 (n ¼ 6e8 per group).
Surgical procedure
Rats were first anesthetized with urethane (1.5 g/kg, supplemented if needed to reduce spontaneously occurring gamma oscillations) with an intraperitoneal (i.p.) injection. Under anesthesia, a femoral vein cannula (P50 tubing) was inserted and rats were placed in a stereotaxic frame (Kopf) and kept at 37.5 C via a heating pad (CMA 150, CMA Microdialysis AB, Denmark). Two small holes were drilled into the cranium to accommodate a stimulating electrode in the nPO (coordinates relative to bregma in mm (Paxinos and Watson, 1986) : AP (anterior posterior): À8.0 mm, L (lateral): À1.6 mm, V (ventral): À6 mm) and a recording electrode in the mPFC (AP: 3.2 mm, L: À0.5 mm, V: À2.5 mm). A platinum wire was placed in the frontal bone to act as a reference electrode.
Electrophysiological recordings and stimulation
Local field potentials (LFP) were recorded using unipolar stainless steel electrodes (0.125 mm in diameter, Plastics One Inc., USA). LFP signals were amplified and filtered between 0.1 and 100 Hz (50 Hz notch filter off) (DP-311, Warner instruments, USA). The amplified LFP signals were digitalized (CED Micro-1401-3, Cambridge Electronic Design, UK) and sampled at 1 kHz for off-line analysis (Spike2 software version 7.10, Cambridge Electronic Design Limited, UK). The nPO was stimulated via a bipolar concentric tungsten electrode 3in (TM53CCINS, World Precision Instruments Inc., USA) with 0.3 ms square pulses delivered over 6 s at 250 Hz, repeated every 100 s (A365R, World Precision Instruments Inc., USA). Stimulation started at 0.025 mA for 40 min. To establish baseline amplitude levels, the stimulating intensity required to elicit gamma rhythm was adjusted to obtaiñ 50% of the maximal gamma response during stimulation under control conditions. After a stable baseline of 30 min was established, idalopirdine or vehicle was administered and EEG recorded for 60 min before a second dose of donepezil or vehicle was injected. Only studies where a stable baseline was established before drug injection were included in the data analysis. Epochs with high amplitude electrical noise were visually identified and manually removed before data analysis. When electrical noise occurred during the entire experiment, this was categorized as failed and data were not used. At the end of each experiment, a 200 mA current was applied through the electrodes, rats were euthanized by cervical dislocation and brains were removed for verification of electrode placement. Only experiments in which electrodes were correctly placed were included in the data analysis.
Data analysis
The signal processing of LFP activity was computed in MATLAB, using functions implemented in the Fieldtrip toolbox (http://www. ru.nl/fcdonders/fieldtrip/) and the sigTOOL toolbox (http://sigtool. sourceforge.net/sigtool.html).
2.1.5.1. Pre-processing. The recordings were read into MATLAB and segmented into epochs from 5 s before stimulation onset to 5 s after nPO offset. The epochs were baseline corrected, to remove any standing offset, by subtracting the average amplitude in the prenPO period from the entire epoch. Artefact correction was then performed for each recording, based on the standard score (z EEG,t ) of each sample:
Any sample with an extreme value, i.e. 15 standard scores from the mean, was considered an artefact. The artefacts were excluded from analysis.
2.1.5.2. Spectral analysis and statistics. To investigate the effect of nPO-stimulation itself and the impact of the treatments, power spectra were computed using a fast Fourier transform between 1 and 90 Hz with a Hamming window on 5 s epochs. Where relevant, frequency bands were compared by Wilcoxon signed rank test (Fig. 1A and B) . Further investigation of a treatment effect was completed by performing a short-time Fourier transform using a fixed 1 s Gaussian window on each epoch in the frequency interval 1e90 Hz. The treatment response over time was computed using the average raw power over time before and during each epoch; pre-stimulation (À5e0 s) and during nPO stimulation (the last 5 s of the 6 s nPO-period were used). To visualize a power change from baseline, the power was normalized to the 30 min average baseline power prior to the first treatment in each frequency bin for each individual animal. Subsequently, oscillatory activity was divided into the 5 main frequency bands: delta; 0e4 Hz, theta; 4e8 Hz, alpha; 8e13 Hz, beta; 13e30 Hz, gamma; 30e90 Hz and compared between treatments. The data are expressed as group mean ± SEM. Data were analyzed by two-way repeated measures ANOVA with treatment (veh/veh, veh/DPZ0.3, IDL1/DPZ0.3, IDL2/DPZ0.3, veh/ DPZ1, IDL2/DPZ1) as between-subject factor and time as within-subject factor, followed by a Holm Sidak post hoc analysis, using SigmaPlot (version 11.0).
2.2. qEEG in the frontal cortex of the freely moving rat 2.2.1. Animals
All animal care and experimental procedures complied with guidance on the care and use of laboratory animals by Lundbeck's IACUC and the US National Research Council (2011). Male SpragueDawley rats (250e300 g) from Charles River were individually housed under a 12 h light/dark cycle (lights on at 06:00 h) and temperature-(21 ± 2 C) and humidity-(60± 10%) control with chow and water available ad libitum.
Drugs
Idalopirdine (IDL, Lundbeck) was dosed at 10 mg/kg, per oral (p.o.) in 5% HP-Beta-CD (2-hydroxypropyl-beta-cyclodextrin) vehicle. Donepezil (DPZ, Tocris Biosciences, UK) was dosed 2 h following either idalopirdine (IDL) or vehicle (veh) at 1 mg/kg or 3 mg/kg, subcutaneously (s.c.) in 5% HP-Beta-CD vehicle. The following dosing paradigms were used in the EEG study (treatment 1 followed by treatment 2): veh/veh, IDL/veh, veh/DPZ1, IDL/DPZ1, veh/DPZ3 and IDL/DPZ3 (n ¼ 7e9 per group).
Surgical procedure
Stainless-steel screw electrodes for EEG and wire electrodes for EMG of dorsal neck muscles were implanted in each animal under anesthesia as described previously Dale et al., 2014; Vogel et al., 2002; Bastlund et al., 2004) . Briefly, bipolar (differential) EEG screw electrodes were placed supradural approximately 2.0 mm anterior and 2.0 mm lateral to bregma bilaterally for frontal cortical EEG and intrahemispheric at 4.0 mm posterior and 2.0 mm lateral to bregma for fronto-parietal EEG. Electrodes were connected to a sterile multi-channel telemetric device (TL10M3-F50-EEE; Data Sciences International, DSI) that was implanted s.c. on the flank. These transmitters also digitally monitored locomotor activity (LMA) which was used in sleep staging. LMA counts were calculated using Dataquest A.R.T software (DSI, St. Paul, Minnesota, USA) as a function of alterations in transmitter signal strength as the animal moved through the receptive field of the receiver located beneath the animal's home cage.
Polysomnographic EEG recordings
EEG Recordings were started 90 min before the first treatment (~9:00 a.m.; 3 h into light cycle) and continued for up to 120 min after the second treatment, using Dataquest A.R.T software (DSI) at a sampling rate of 500 Hz. Offline, using NeuroScore (DSI), artefacts, detectable as incongruent periods of non-physiological, electrical activity, were manually scored as such and removed from analyses. The main types of artefacts were: i. Movement artefacts typically traversing all EEG and EMG signals, readily detected by a uniform (non-chaotic) signal of large amplitude outside the physiological range (e.g. >500 mV), ii. Line noise (60 Hz) or any continuous, nonphysiological frequency pattern that would be considered noise from external powered sources, iii. EEG that does not fall within normal amplitude of operation (e.g. physiological range: typically greater than 100 mV and less than 500 mV). EEG that drops below this minimum, or "drop-out", is typically indicative of a loss of signal fidelity (e.g. battery low or electrode grounding/wire issue), whereas EEG that is maintained above this maximum ("maxes out"), is often caused by an electrode grounding/wire issue. iv. EEG activity contaminated by cardiac events. Rats that exhibited the above artefacts either routinely, or for greater than 20% of the time during a recording, were not included in analyses.
Following artefact correction, sleep stages were assigned manually for every 10 s epoch using fronto-parietal EEG, EMG and LMA by conventional methods as previously described (Ivarsson et al., 2005; Parmentier-Batteur et al., 2012; Leiser et al., 2015) . Briefly, sleep stages were determined using the following criteria: active wake (less regular, low amplitude EEG with high EMG and LMA); quiet wake (less regular, low amplitude EEG, with low EMG, and no LMA); NREM or slow wave sleep (high-amplitude waves dominated by delta (1e4 Hz), low EMG and no LMA); paradoxical or REM sleep (stable, low-amplitude waves dominated by theta (4e8 Hz) with near absent EMG and no LMA). Sleep scoring relied on a two-part process using an optimized automated detection algorithm employed by Neuroscore (DSI), with a careful manual examination of each 10 s epoch for congruity with the above criteria. The Automated Scoring method is not as reliable or accurate as manual scoring and thus manual scoring was performed on all recordings. All data were scored into the four sleep stages, however qEEG data are only shown for active wake in this paper in order to maximize the likelihood of translatability (Maire et al., 2013) . 2.2.5. Data analysis 2.2.5.1. EEG data. Gamma spectral power (30e90 Hz) during active wake state was calculated in NeuroScore (DSI) with a 1 Hz resolution. Heatmaps were created using Matlab (Mathworks). Pharmacologically induced changes in the EEG were evaluated by averaging the 10 s epochs constituting the 90 min before the first treatment ('baseline') and each 30 min bin post-treatment until 120 min after the second treatment. The time period of 120 min following donepezil administration was chosen as separate exposure studies indicated clinically relevant plasma exposure of donepezil within this timeframe (>50 ng/ml in plasma) (Tiseo et al., 1998) . To visualize a power change from baseline, the power was normalized to the 90 min average baseline power prior to the first treatment in each frequency bin for each individual animal. The data are expressed as group mean ± SEM. Data were analyzed by two-way repeated measures ANOVA with treatment (veh/veh, IDL/ veh, veh/DPZ1, IDL/DPZ1, veh/DPZ3 and IDL/DPZ3) as betweensubject factor and time (4 bins of 30 min each) as within-subject factor, followed by an LSD post hoc analysis, using SigmaPlot (version 11.0).
Sleep stages.
Quantitative analysis of each sleep stage (REM, NREM, quiet wake and active wake) was calculated as the percent time spent in each sleep stage during the 120 min after the second treatment. The REM and NREM onset latencies were determined as the first epoch of REM or NREM, respectively, lasting greater than 20 s, represented in minutes after the second treatment. As sleep onset did not occur within the 120 min after the second treatment in all treatment groups, animals were monitored for up to 240 min to establish REM and NREM onset. Data were analyzed by one-way ANOVA followed by Bonferroni post-hoc analysis using SigmaPlot (version 11.0).
Plasma and brain exposure of idalopirdine and donepezil

Tissue and plasma collection
In the nPO stimulation assay, plasma and brain concentrations of donepezil and idalopirdine were measured in a selection of animals (indicated in Fig. 4 ) at the end of the recording, being 120 min after idalopirdine/vehicle treatment and 60 min after donepezil/ vehicle administration. At the terminal time point, a blood sample was taken by heart puncture and kept in 1.6 mg EDTA/mL of blood. Rats were euthanized by cervical dislocation as described previously, brains were dissected out and stored at À80 C until they were sectioned at 20 mm on a cryostat (CM3050S, Leica Biosystems, UK) in serial coronal slices to inspect for electrode placement. Blood samples were centrifuged for 10 min at 5000 g at 4 C and plasma was stored at À80 C until bioanalysis.
In the EEG study, compound exposure was not investigated as animals were, for another purpose, monitored for a total of 24 h. Compound concentrations at the terminal time point would not reflect those during the EEG recordings.
Quantitative bioanalysis
Rat plasma and brain concentrations of idalopirdine and donepezil were determined using Ultra performance liquid chromatography coupled to tandem mass spectrometry (MS/MS). Brain homogenate samples were prepared by homogenizing the whole brain with 70% acetonitrile (1:4, v/v) followed by centrifugation and collection of the supernatant. Plasma or brain samples (25 ml) were precipitated with 150 ml acetonitrile containing internal standard.
For idalopirdine, 13C-labelled internal standard was used. After centrifugation, 100 ml supernatant from each sample was transferred to a new plate and mixed with 100 ml 0.1% formic acid. After a quick centrifugation the samples were placed in the autosampler.
Chromatography was performed on a Waters Aqurity C18 SB HSS column (30 Â 2.1 mm, 1.8 mm particles) using a mobile phase gradient of 0.1% formic acid in water and acetonitrile pumped through the column with a flow rate of 0.6 ml/min. The retention times were 1.13 and 0.93 min for idalopirdine and donepezil respectively. MS/MS detection was performed with an Applied Biosystems Sciex API 4000 instrument in positive-ion electrospray ionization mode (AB Sciex, Foster City, CA). Mass to charge ratios (m/z) of 399.1 > 221.1 and 380.2 > 91.2 were used for detection of idalopirdine and donepezil, respectively. Nitrogen was used for the nebulizer and collision gases. The peak area correlated linearly with the concentration in the range of 0.5e1000 ng/ml in plasma and 2.5e5000 ng/g in brain for both analytes. Data acquisition and analysis was performed using Analyst software, version 6.1 (AB Sciex, Foster City, CA).
Data analysis
Plasma and brain concentrations of the compounds were analyzed by a Kruskall-Wallis test followed by Dunn's post-hoc test using SigmaPlot (version 11.0).
Results
3.
1. The effect of idalopirdine in combination with donepezil on gamma rhythm during nPO stimulation in the anesthetized rat 3.1.1. Effect of electrical stimulation of the nPO on oscillatory activity in the mPFC
To establish baseline amplitude levels, a stimulation input/ output (I/O) curve was determined at the beginning of every experiment. Increasing stimulation intensity was closely correlated with increases in amplitude of gamma rhythm in the mPFC in rats. The average intensity of all experiments to elicit 50% of the maximal gamma amplitude under control conditions was 46 mA ± 15 (data not shown, see Supplementary Fig. 1 for a representative experiment). No correlation was found between stimulation intensity and gamma frequency.
Electrical stimulation of the nPO significantly suppressed low frequency delta (0e4 Hz) and theta (4e8 Hz) oscillations (Wilcoxon singed rank test, p < 0.001) replacing them with high frequency gamma oscillations (30e90 Hz) (Wilcoxon singed rank test, p < 0.001) in the mPFC (Fig. 1A) .
Systemic administration of the vehicles (glucose 5% and saline 0.9%, 1 ml/kg i.v.) did not significantly affect any frequency rhythms and therefore, the data from the vehicle group were used as control (Fig. 1B ). There were no treatment effects on oscillations prestimulation (Fig. 2, left panel) , therefore compound effects are described during nPO stimulation (Fig. 2, right panel and Fig. 3 ).
Effect of idalopirdine on gamma power in the mPFC during nPO stimulation
Idalopirdine dose-dependently increased gamma power during electrical stimulation of the nPO when compared to vehicle treatment during the first 30 min after administration (F Fig. 3A) . Idalopirdine 1 mg/kg i.v. did not significantly increase gamma power as compared to vehicle treatment. In contrast, idalopirdine 2 mg/kg i.v. significantly increased gamma power as compared to vehicle treatment between 18 and 22 min after administration, and as compared to idalopirdine 1 mg/kg treatment at the time points indicated in Fig. 3A (p < 0.05). Gamma power peaked at~150% of the baseline following treatment with idalopirdine 2 mg/kg.
In addition, idalopirdine 2 mg/kg slightly decreased low Fig. 3B ). At isolated time points, both doses of donepezil (0.3 and 1 mg/kg, i.v.) significantly increased gamma power as compared to vehicle treatment (p < 0.05, Fig. 3B ) but overall no treatment effect was reached. This occurred earlier following treatment with donepezil 0.3 mg/kg (between 8 and 25 min after administration) than for donepezil 1 mg/kg (between 20 and 46 min). Gamma power peaked at~140% of the baseline following treatment with either dose of donepezil, however this response was maintained longer with the 1 mg/kg as compared to the 0.3 mg/kg dose (46 vs. 25 min after administration, respectively). There was no statistically significant difference between donepezil 0.3 and 1 mg/kg treatment. No further potentiation of gamma power was obtained by increasing the dose of donepezil to 3 mg/kg or by increasing the stimulation intensity (data not shown). Lower frequency oscillations were not significantly affected by donepezil treatment (p > 0.05).
Effect of idalopirdine in combination with donepezil on gamma power in the mPFC during nPO stimulation
Idalopirdine significantly potentiated and/or prolonged the effect of the low dose of donepezil (0.3 mg/kg) on gamma power during nPO stimulation in the 60 min after donepezil administration (F[treatment] Fig. 3C ). Idalopirdine 2 mg/kg in combination with donepezil 0.3 mg/kg significantly increased gamma power as compared to vehicle treatment (overall treatment effect: p < 0.01), while there was no significant overall effect of donepezil 0.3 mg/kg alone. The response to idalopirdine 2 mg/kg in combination with donepezil 0.3 mg/kg was significantly different from vehicle treatment from 8 to 40 min after donepezil administration (p < 0.05), peaking at~180% of baseline and plateauing at~150% for the rest of the recording period. In contrast, the response to donepezil 0.3 mg/kg alone transiently peaked at~140% of baseline. Thus, idalopirdine 2 mg/kg potentiated and prolonged the effects of donepezil 0.3 mg/kg on gamma power.
Also idalopirdine 1 mg/kg in combination with donepezil 0.3 mg/kg significantly increased gamma power as compared to vehicle treatment from 5 to 22 min after donepezil administration (p < 0.05) and potentiated the effect of donepezil 0.3 mg/kg alone during the peak effect, 8e10 min after administration (p < 0.05). The response to idalopirdine 1 mg/kg in combination with donepezil 0.3 mg/kg peaked at~200% of the baseline, not being significantly different from the peak effect observed with idalopirdine 2 mg/kg in the combination treatment (~180%). However, the effect of idalopirdine 1 mg/kg was not sustained throughout the recording period as was observed with idalopirdine 2 mg/kg. Thus, whereas both doses of idalopirdine (1 and 2 mg/kg) potentiated the effects of donepezil 0.3 mg/kg on gamma power, the effect of idalopirdine 1 mg/kg was transient whereas the effect of idalopirdine 2 mg/kg was sustained throughout the recording period.
Idalopirdine 2 mg/kg also significantly potentiated the effect of the high dose of donepezil (1 mg/kg) on gamma power during nPO stimulation in the 60 min after donepezil administration (F Fig. 3D ). Idalopirdine 2 mg/kg in combination with donepezil 1 mg/ kg significantly increased gamma power as compared to vehicle treatment (overall treatment effect: p < 0.05) and as compared to donepezil 1 mg/kg alone at selected time points indicated in Fig. 3D (p < 0.05). The response to idalopirdine 2 mg/kg in combination with donepezil 1 mg/kg was significantly different from vehicle treatment from 15 to 45 min after donepezil administration (p < 0.05) peaking at~180% of the baseline, not decreasing below 150% during the significant period. In contrast, the response to donepezil 1 mg/kg alone peaked and plateaued at~140%. Thus, idalopirdine 2 mg/kg potentiated the effects of donepezil 1.0 mg/kg on gamma power. Analysis of the different treatments over time as compared to vehicle treatment revealed that none of the treatments significantly modulated the power of other frequency bands (p > 0.05).
Plasma and brain exposure of idalopirdine and donepezil in the nPO stimulation assay
In the nPO stimulation assay, plasma and brain concentrations of idalopirdine and donepezil were determined in a selection of animals at the end of the recording, 120 min after idalopirdine treatment and at 60 min after donepezil treatment, respectively (Fig. 4) . Donepezil concentrations in plasma (H ¼ 21.82, p < 0.001) and brain (H ¼ 18.61, p < 0.001) increased in a dose-dependent manner, being higher following treatment with donepezil 1 mg/ kg i.v. as compared to 0.3 mg/kg i.v. (at least p < 0.05 for selected groups, indicated in Fig. 4A and B) . There was no significant effect of idalopirdine (1 or 2 mg/kg, i.v.) pretreatment on donepezil concentrations at either dose of donepezil.
Idalopirdine concentrations increased in a dose-dependent manner in both plasma (H ¼ 15.24, p < 0.001) and brain (H ¼ 12.68, p < 0.001) and were significantly higher in the groups receiving idalopirdine 2 mg/kg i.v. as compared to 1 mg/kg i.v. (at least p < 0.05, Fig. 4C and D) . There was no significant effect of donepezil (0.3 vs. 1 mg/kg i.v.) on the concentration of idalopirdine (2 mg/kg i.v.) in plasma and brain.
The effect of idalopirdine in combination with donepezil on gamma rhythm in the frontal cortex in freely moving rats
Given the treatment effects on gamma power in the nPO stimulation assay, we investigated the effect of idalopirdine, donepezil and the combination on cortical gamma oscillations in freelymoving rats. There was no change in locomotor activity as measured by the DSI transmitter in any of the treatment groups for the times tested (data not shown, ANOVA, F 25,1860 ¼ 0.888, p ¼ 0.623). Gamma spectral power (30e90 Hz), investigated during active wake, is represented in the heatplots (Fig. 5) and quantified for each 30 min bin from 90 min before the first treatment (baseline) to 120 min after the second treatment (Fig. 6) . Idalopirdine (10 mg/kg p.o.) alone had no effect on gamma power during the 120 min period after administration. Donepezil, administered 2 h after idalopirdine or vehicle, dose-dependently increased gamma power in the 120 min period after administration (F [treatment] Fig. 6 ). Both donepezil 1 mg/kg and 3 mg/kg s.c. increased gamma power as compared to vehicle treatment (p < 0.05 and p < 0.001, respectively) and gamma power was further increased by 3 mg/kg as compared to 1 mg/kg donepezil (p < 0.05). Idalopirdine (10 mg/kg) significantly potentiated the effect of donepezil 1 mg/kg on gamma power (p < 0.05), whereas there was no further potentiation of the response to donepezil 3 mg/kg by idalopirdine (p ¼ 0.502).
In addition, donepezil (1 and 3 mg/kg s.c.) alone significantly decreased alpha power as compared to vehicle treatment (p < 0.05) in the 120 min period after administration, while idalopirdine (10 mg/kg p.o.) alone had no effect (F[treatment] Supplementary Fig. 2 ). There was no statistically significant difference between the two doses of donepezil. Idalopirdine (10 mg/kg p.o.) in combination with donepezil 1 mg/kg did not result in a significant decrease in alpha power as compared to vehicle treatment, suggesting that pretreatment with idalopirdine attenuates the effect of donepezil 1 mg/kg on alpha power. In contrast, pretreatment with idalopirdine did not modulate the effect of donepezil 3 mg/kg on alpha power.
Analysis of the different treatments over time as compared to vehicle treatment revealed that none of the treatments Table 1 ). Both doses of donepezil delayed REM onset as compared to vehicle treatment (p < 0.05 and p < 0.001 for donepezil 1 and 3 mg/kg s.c., respectively) and REM onset was further delayed following treatment with donepezil 3 mg/kg as compared to 1 mg/kg (p < 0.001). Donepezil 3 mg/kg also delayed the onset of NREM sleep (F[treatment] Fig. 7A and B). Both doses of donepezil reduced the time spent in REM and NREM sleep as compared to vehicle treatment (p < 0.001) and donepezil 3 mg/kg further reduced the time spent in both REM and NREM sleep in comparison to donepezil 1 mg/kg (p < 0.05 and p < 0.001 for REM and NREM, respectively). Idalopirdine (10 mg/kg) did not modulate the percentage of time spent in REM or NREM sleep, nor the effect of either dose of donepezil ( Fig. 7A and B) .
Conversely, donepezil dose-dependently increased the time spent in quiet wake (F[treatment] 5,47 ¼ 68.08, p < 0.0001, Fig. 7C ). Both doses of donepezil increased the time spent in quiet wake as compared to vehicle treatment (p < 0.001) and donepezil 3 mg/kg further increased the time spent in quiet wake in comparison to donepezil 1 mg/kg (p < 0.001). Idalopirdine (10 mg/kg) did not modulate the percentage of time spent in quiet wake, nor the effects of donepezil (Fig. 7C ). There were no treatment effects on active wake, with the exception of an increase observed in the donepezil 1 mg/kg group (F[treatment] 5,47 ¼ 2.967, p < 0.05, Fig. 7D ).
Discussion
In the present study we demonstrate that treatment with the 5-HT 6 receptor antagonist idalopirdine (Lu AE58054) alone enhanced cortical gamma power under strong afferent drive, but further, with the AChEI donepezil present, enhanced gamma power to a greater extent than either cholinesterase inhibition or 5-HT 6 antagonism alone. In contrast, idalopirdine did not affect sleep-wake architecture nor did it modify the effects of donepezil. We discuss in the context of two in vivo electrophysiological assays, neuronal oscillations during nPO stimulation in the anesthetized rat and sleepstage controlled qEEG in the freely-moving rat, the effects of donepezil, idalopirdine and the combination of both on cortical excitability and on sleep-wake architecture.
Effects of donepezil, idalopirdine and the combination on oscillatory activity in the mPFC during stimulation of the nPO
In anesthetized rats, high frequency stimulation of the brainstem nPO evoked gamma oscillations and reduced delta and theta oscillations in the mPFC. This finding is consistent with previous reports showing that stimulation of various nuclei of the reticular formation suppresses low frequency oscillations replacing them with high frequency oscillations in the cortex (Dringenberg and Olmstead, 2003; Wu et al., 2007) . Effects of the treatments on the onset of REM and NREM sleep. Idalopirdine (IDL) or vehicle (veh) were administered 120 min prior to donepezil (DPZ) or veh. Onset was defined as the first epoch of REM or NREM, lasting greater than 20 s following the 2nd treatment. Data are represented as AVG time (min) after the 2nd treatment ± SEM (n ¼ 7e9). *, **p < 0.05 or p < 0.001 vs. VEH/VEH, ##p < 0.001 vs DPZ1 with similar pretreatment. Fig. 7 . Effect of idalopirdine, donepezil and the combination on sleep-/wake architecture in the freely moving rat. Effects of the treatments on REM and NREM sleep, quiet and active wake. Idalopirdine 10 mg/kg p.o. (IDL) or vehicle (veh) were administered 120 min prior to donepezil 1 or 3 mg/kg (DPZ1 or DPZ3) or veh. Data are represented as AVG time spent (%) in each phase in the 120 min after the 2nd treatment ± SEM (n ¼ 7e9). *, **p < 0.05 or p < 0.001 vs. VEH/VEH, # , ## p < 0.05 or p < 0.001 vs DPZ1 with similar pretreatment. ns ¼ non-significant.
Previously, donepezil has been reported to induce gamma oscillations in rat hippocampal slices (Spencer et al., 2010) and in the hippocampus of the anesthetized rat during electrical stimulation of the nPO (Herrik et al., 2016) . To our knowledge, this is the first study showing that a procognitive drug, donepezil (0.3 and 1.0 mg/ kg i.v.), selectively augments gamma oscillations in the mPFC during nPO stimulation under urethane anesthesia, suggesting that stimulation-induced cortical gamma oscillations are sensitive to procognitive compounds. However, the effects of donepezil may have a ceiling effect, as demonstrated by Spencer et al. for donepezil-induced gamma oscillations in hippocampal slices (Spencer et al., 2010) . This is supported by the findings in our nPO assay, as the peak response to both doses of donepezil was similar (~140% of baseline), though maintained longer with donepezil 1 as compared to 0.3 mg/kg. Furthermore, increasing the dose of donepezil beyond 1 mg/kg did not further increase gamma power in the mPFC (data not shown). Yet, the efficacy of both doses of donepezil (0.3 and 1 mg/kg) to increase cortical gamma oscillations was further potentiated by pretreatment with the 5-HT 6 receptor antagonist idalopirdine. We previously demonstrated that donepezil at the dose of 0.3 mg/kg i.v. results in plasma concentrations in the clinically relevant range in the time frame where oscillatory activity peaks, and that these are not altered by pretreatment with idalopirdine (Herrik et al., 2016 ). In the current study, we confirmed that plasma and brain exposure of donepezil were not modulated by co-administration of idalopirdine. Thus, we conclude that, in the nPO model, idalopirdine potentiates the effects of clinically relevant concentrations of donepezil on gamma oscillations in the mPFC. Similarly, we have recently shown that idalopirdine potentiates and prolongs the effects of donepezil on theta and gamma power during nPO stimulation in the hippocampus of the rat (Herrik et al., 2016) . These parallel treatment effects in the hippocampus and mPFC support the coherence in oscillatory activity observed between the dorsal hippocampus and the mPFC during nPO stimulation (Kiss et al., 2013) and synchronization of network activity between these two brain regions is likely to play a role during performance of a cognitive task (Jones and Wilson, 2005; Kiss et al., 2013) .
Interestingly, idalopirdine (2 mg/kg i.v.) as a monotherapy also increased the effect of nPO stimulation by increasing gamma power and slightly reducing slower oscillations (1e8 Hz) in the mPFC, with an increase in gamma power of a similar magnitude to that of donepezil alone (~150 vs.~140%). This indicates that both 5-HT 6 receptor antagonism and cholinesterase inhibition can independently facilitate oscillatory activity in the mPFC in this assay. Moreover, higher peak responses were obtained with the combination of idalopirdine 2 mg/kg with either dose of donepezil (~180%), indicating that the effects of both compounds are, at least partially, cumulative. Whether there is a synergy between both mechanisms or whether the effects of both treatments are additive, cannot be concluded from the present data, but earlier observations that 5-HT 6 receptor antagonists potentiate the effects of donepezil on ACh levels are suggestive of an, at least partially, synergistic mechanism (Dawson, 2011; Herrik et al., 2016) . Interestingly, only the high dose of idalopirdine (2 mg/kg i.v.) increased gamma oscillations as a monotherapy. Furthermore, whilst both doses of idalopirdine (1 and 2 mg/kg i.v.) potentiated the effects of donepezil 0.3 mg/kg on gamma power, only with the high dose (2 mg/kg i.v.) was this effect sustained throughout the recording period. At the 2 mg/kg i.v. dose, idalopirdine concentrations were around 100 ng/ ml in plasma which is well above previously reported plasma concentration of 20 ng/ml leading to 50% occupancy of the 5-HT 6 receptors in vivo in rats (Arnt et al., 2010) . The minimally required receptor occupancy is not precisely known but it is assumed that quite high 5-HT 6 receptor occupancy, above 60%, is required for the procognitive effects (Arnt et al., 2010) .
4.2. Effects of donepezil, idalopirdine, and the combination on oscillatory activity in the frontal cortex in awake spontaneous qEEG Also in the awake freely moving rat, donepezil (1 and 3 mg/kg s.c.) dose-dependently enhanced cortical gamma power, an observation which is consistent with the previously published report by Ahnaou and colleagues (Ahnaou et al., 2014) . Furthermore, in line with our findings in the nPO stimulation model, idalopirdine (10 mg/kg p.o.) pretreatment further potentiated the effects of donepezil 1 mg/kg on gamma power in the frontal cortex. In contrast, the effect of donepezil 3 mg/kg on gamma power was not further potentiated by idalopirdine and at this dose of donepezil a ceiling in the gamma response may have been reached.
In exposure studies (data not shown), we established that the dose of 1 mg/kg s.c. donepezil resulted in plasma concentrations within the clinically relevant range (50e100 ng/ml up to 2 h after administration) (Tiseo et al., 1998) , whereas concentrations above the therapeutic range were obtained with donepezil 3 mg/kg (250 ng/ml) (Tiseo et al., 1998; Gomolin et al., 2011) . It is therefore concluded that idalopirdine increases the effect of a clinically relevant concentration of donepezil on frontal cortical gamma power in the EEG of the freely moving rat.
Interestingly, although idalopirdine (2 mg/kg i.v.) acted as a monotherapy and increased cortical gamma in the nPO assay, idalopirdine (10 mg/kg, p.o.) did not elicit an increase in cortical gamma in the spontaneous qEEG of awake freely-moving rats, despite the fact that high receptor occupancy in the brain was achieved in both assays (Arnt et al., 2010; Herrik et al., 2016) . The different placement of the electrodes in these two assays could partly explain the differential effects observed with idalopirdine alone. In addition, this discrepancy could be explained by the fact that in the EEG study, rats were in their home cage and although awake and exploring their environment, they were not receiving any particularly salient or cognition-demanding cues. In contrast, electrical stimulation of the nPO would provide an inherent drive to cortical afferents, encompassing excitatory input from the hippocampus and thalamocortical projections (Thierry et al., 2000; Steriade, 1999) . Thus, we propose that it is under this higher afferent (signal) load that 5-HT 6 receptor antagonism functions to increase signal-to-noise as a monotherapy (Pinault, 2014) . In the case of the spontaneous EEG, there may not be sufficient afferent drive to reveal this monotherapy effect. However, in the presence of donepezil, the cholinergic system is able to enhance thalamocortical drive to the cortical afferents, as thalamocortical inputs in the sensory cortex were shown to be facilitated in an ACh concentration-dependent manner (Dringenberg et al., 2007; Deco and Thiele, 2011; Kang et al., 2014) . We propose that under this greater afferent activation mediated by donepezil, the 5-HT 6 receptor antagonist idalopirdine now potentiates this effect. The potential mechanisms are discussed in greater detail below.
Analogous to the observations by Ahnaou et al., 2014 , donepezil (1 and 3 mg/kg s.c.) decreased cortical alpha power in the spontaneous qEEG of awake freely-moving rats. Idalopirdine (10 mg/kg p.o.) attenuated this decrease in cortical alpha power at the low dose of donepezil (1 mg/kg s.c.), while it did not modulate the effect of the high dose of donepezil (3 mg/kg s.c.). Alpha frequency, although the first frequency characterized, seems to be the most complicated in interpretation and identifying its generators or sources. In addition, there are fundamental differences between rodent and man in alpha rhythm (Shaw, 2013) . Therefore, the implications of these changes in cortical alpha activity require further investigation.
The role of 5-HT 6 receptor antagonism in cortical excitability
There are several possible mechanisms through which 5-HT 6 receptor antagonism may modulate cortical gamma oscillations. We have recently demonstrated that idalopirdine potentiates the effect of donepezil on extracellular levels of ACh in both the hippocampus and the mPFC of the rat (Foraster et al., 2014; Herrik et al., 2016) , which is in agreement with two other studies showing that 5-HT 6 receptor antagonism potentiates cholinergic signaling in the PFC (Riemer et al., 2003; Hirst et al., 2006) . The cholinergic system is known to be crucial for triggering theta and gamma oscillations in the hippocampus and cortex. For example, gamma oscillations can be induced in hippocampal and cortical slice preparations by cholinergic receptor activation with carbachol and with the AChEIs physostigmine and donepezil (Buhl et al., 1998; Traub et al., 2000; Fellous and Sejnowski, 2000; Spencer et al., 2010; Pietersen et al., 2014) . Furthermore, nicotine and the AChEI neostigmine have been shown to induce gamma oscillations in the hippocampus in vivo (Joosen and van Helden, 2007; Phillips et al., 2007; Ahnaou et al., 2014) . We therefore propose that by locally increasing the levels of ACh in the frontal cortex, idalopirdine may potentiate the effects of donepezil on gamma oscillatory activity in this brain region.
The cellular localization of the 5-HT 6 receptor provides further insight into the potential mechanism through which idalopirdine facilitates neuronal oscillations. We have recently demonstrated that 5-HT 6 receptor mRNA is expressed by pyramidal cells throughout the cortical regions and in the hippocampus as well as by a subset of GABA-ergic interneurons (approximately 15%), the majority of which belonged to the 5-HT 3a receptor-expressing subpopulation. A subset of calbindin (CB)-and calretinin (CR)-positive GABA-ergic interneurons also expressed 5-HT 6 receptor mRNA (Helboe et al., 2015) . Gamma oscillations are driven by phasic inhibition from GABA-ergic interneurons that modulate activity of excitatory glutamatergic pyramidal neurons (Cardin et al., 2009; Traub et al., 1999; Whittington et al., 1995) . The commonly accepted origin of inhibition underlying gamma rhythms is the fast spiking, perisomatic targeting, parvalbumin (PV) positive basket cell (Cardin et al., 2009; Gulyas et al., 2010) and gamma rhythms resulting from synchronization of PV fast spiking interneurons have been linked to PFC-dependent cognitive flexibility and attention (Cho et al., 2015; Kim et al., 2016) . However, PV positive interneurons are nearly devoid of 5-HT 6 receptor mRNA (Helboe et al., 2015) . Interestingly, 5-HT 3a expressing interneurons were shown to modulate gamma oscillations in the hippocampus by regulating synchrony of PV fast spiking interneurons and idalopirdine may facilitate gamma oscillations through modulation of this cell type (Huang et al., 2014) . Later studies have shown the involvement of multiple types of interneurons in the generation of cortical gamma rhythms (Whittington et al., 2011) and it will be of great future interest to study the specific contributions of 5-HT 3a receptor, CR and CB positive interneurons as well as pyramidal neurons, to the effects of idalopirdine on neuronal oscillations and cognition.
4.4. Effects of donepezil, idalopirdine, and the combination on sleep-wake architecture in the freely moving rat Donepezil dosed at the beginning of the light cycle, during which nocturnal animals sleep, dose-dependently promoted wakefulness by delaying the onset of sleep and, as a consequence, reducing the time spent in both NREM and REM sleep stages. These findings are in agreement with an earlier study with donepezil in the freely moving rat (Ishida and Kamei, 2009) . Also in AD patients, insomnia and other sleep disorders (abnormal dreams, vivid dreams and nightmares) have been reported following the administration of donepezil Wilkinson, 1999; Burns et al., 1999; Jackson et al., 2004) . It has been proposed that these effects are related to the exposure of the compound during the night time and might be prevented by morning administration (Jackson et al., 2004; Song et al., 2013) . In contrast, donepezil has also been suggested to enhance REM sleep in AD patients, which is in agreement with the role of acetylcholine in promoting REM sleep (Ringman and Simmons, 2000; Moraes et al., 2006) . The reduction in both NREM and REM sleep observed with donepezil in the current study reflects the increased latency to sleep and does not allow for further conclusions on the quality or nature of sleep.
The serotonergic system is also well recognized for its role in sleep regulation, although the contribution of the 5-HT 6 receptor is not well investigated. Two studies have demonstrated that 5-HT 6 receptor agonism promotes wakefulness in the rat (Monti et al., 2013; Ly et al., 2013) , whereas 5-HT 6 receptor antagonism was reported to either promote sleep (Morairty et al., 2008) , increase wakefulness (Monti et al., 2013) or have no effect (Ly et al., 2013 ). Here we demonstrate that idalopirdine alone does not affect sleepwake architecture in the freely moving rat, in agreement with the Ly study (Ly et al., 2013) , and does not modulate the wakepromoting effects of donepezil. The observation that idalopirdine potentiates the effects of donepezil on cortical and hippocampal excitability, but not on sleep, may be explained by the fact that 5-HT 6 receptor expression is very low in the brainstem regions that mediate the sleep-wake cycle as compared to brain regions that mediate cognition (Helboe et al., 2015) .
Functional implications of the increase in cortical gamma power
Antagonism of the 5-HT 6 receptor appears a promising approach for improving cognition, in particular for AD patients (Ramirez, 2013; Wilkinson et al., 2014) . The current study shows that idalopirdine facilitates cortical gamma oscillations under strong afferent drive and is able to augment donepezil's increase of gamma power, without modifying the effects of donepezil on sleep-wake architecture. Both cortical and hippocampal gamma oscillations are involved in multiple aspects of cognitive and sensory functions such as short-and long-term memory (Engel and Singer, 2001; Kaiser et al., 2008; Kaiser and Lutzenberger, 2005; Ainsworth et al., 2011; Herrmann et al., 2004; Pesaran et al., 2002; Wu et al., 2008) , selective attention (Doesburg et al., 2008; Fries et al., 2001; Lakatos et al., 2008; Tallon-Baudry, 2009; Womelsdorf et al., 2007; Womelsdorf and Fries, 2006) , multisensory integration (Lakatos et al., 2007) as well as memory refreshment and formation and experience-dependent plasticity (Ward, 2003; Jutras and Buffalo, 2010; Fell and Axmacher, 2011; Headley and Weinberger, 2011) . In AD patients, a decrease in cortical gamma power has been described, which can be partially reversed by AChEI treatment (Babiloni et al., 2013; Herrmann et al., 2010) . In rodents, cognition enhancers have been shown to elicit cortical gamma oscillations and coherent activity across different cortical areas (Ahnaou et al., 2014) , although compounds known to induce cognitive impairment (i.e. ketamine) can induce robust increases in state-independent gamma power (Pinault, 2008; Kittelberger et al., 2012; Wood et al., 2012) . Collectively, these observations suggest that gamma oscillations are a useful efficacy index for testing putative procognitive compounds. Therefore, the current observation that idalopirdine enhances cortical excitability in the form of gamma oscillations may represent one of the key mechanisms through which 5-HT 6 receptor antagonism exerts procognitive effects and may ultimately contribute to idalopirdine improving cognitive function in donepezil-treated patients with AD (Wilkinson et al., 2014) .
